ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2011
Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Identification of pathways for bipolar disorder: a meta-analysis.JAMA psychiatry · 2014Pooled it
- Effects of the neurogranin variant rs12807809 on thalamocortical morphology in schizophrenia.PloS one · 2013Trial
- Metabolic Mechanisms in Electroconvulsive Therapy for Schizophrenia: Role, Potential and Future Directions.International journal of molecular sciences · 2026Review
- Biochemical Properties and Physiological Functions of pLG72: Twenty Years of Investigations.Biomolecules · 2022Review
- d-Amino Acids and pLG72 in Alzheimer's Disease and Schizophrenia.International journal of molecular sciences · 2021Review
- Effect of DAOA genetic variation on white matter alteration in corpus callosum in patients with first-episode schizophrenia.Brain imaging and behavior · 2021Article
- Neural correlates of binocular depth inversion illusion in antipsychotic-naïve first-episode schizophrenia patients.European archives of psychiatry and clinical neuroscience · 2019Article
- The PPM1F gene moderates the association between PTSD and cortical thickness.Journal of affective disorders · 2019Article
- Cortical Contributions to Distinct Symptom Dimensions of Catatonia.Schizophrenia bulletin · 2019Article
- D-Amino Acid Oxidase-pLG72 Interaction and D-Serine Modulation.Frontiers in molecular biosciences · 2018Review
- G72 primate-specific gene: a still enigmatic element in psychiatric disorders.Cellular and molecular life sciences : CMLS · 2016Review
- Identification of pLG72-Induced Oxidative Stress Using Systemic Approaches.BioMed research international · 2015Article
- Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia.Molecular psychiatry · 2013Article
- Genetics of brain structure: contributions from the Vietnam Era Twin Study of Aging.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2013Article
- Multimodal functional and structural imaging investigations in psychosis research.European archives of psychiatry and clinical neuroscience · 2012Review
- Genotypic association of the DAOA gene with resting-state brain activity in major depression.Molecular neurobiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In light of current etiological concepts the glutamatergic system plays an essential role for the pathophysiology of the disorder, offering multiple options for new treatment strategies. The D-amino oxidase activator (DAOA) gene is closely connected to the glutamatergic system and its therapeutic and pathophysiological relevance for schizophrenia is therefore intensively debated. In a further step to shed light on the role of DAOA in schizophrenia, we aimed to investigate the association of the functional DAOA Arg30Lys (rs2391191) variant and cortical thickness in schizophrenia. Cortical thickness was computed by an automated surface-based technique (FreeSurfer) in 52 genotyped patients with schizophrenia and 42 healthy controls. Cortical thickness of the entire cortex was compared between risk carriers and non-risk carriers regarding the Arg30Lys polymorphism in patients and healthy controls on the basis of a node-by-node procedure and an automated clustering approach. Risk carriers with schizophrenia show significantly thinner cortex in two almost inversely arranged clusters on the left and right hemisphere comprising middle temporal, inferior parietal, and lateral occipital cortical areas. The clusters encompass an area of 1174 mm(2) (left) and 1156 mm(2) (right). No significant effect was observed in healthy controls.The finding of our study that the Arg30Lys risk variant is associated with a distinct cortical thinning provides new evidence for the pathophysiological impact of DAOA in schizophrenia. The affected areas are mostly confined to cortical regions with a crucial role in the ToM network and visual processing, which both can be influenced by glutamatergic modulation. Our finding thus underlines the importance of DAOA and related glutamatergic processes as a putative target for therapeutic interventions in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.